Research programme: immunotherapies - Selecta Biosciences

Drug Profile

Research programme: immunotherapies - Selecta Biosciences

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Sanofi
  • Developer Sanofi; Selecta Biosciences
  • Class Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Food hypersensitivity
  • Research Coeliac disease

Most Recent Events

  • 10 Nov 2016 Selecta Biosciences acquires rights for immunotherapies from Sanofi
  • 10 Sep 2015 Preclinical trials in Food allergy in USA (Parenteral) (Selecta Biosciences pipeline, September 2015)
  • 13 May 2015 Early research in Coeliac disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top